Navigation Links
VisionGate Uses $2.6 Million NIH Grant to Achieve Full Automation of Cell-CT™ 3D Imaging System for Early Diagnosis of Cancer
Date:1/6/2012

nd Director of the Lung Biopsy Service at the Mount Sinai Medical Center in New York City.  "But the large number of individuals at high risk for developing this disease, which kills more than 160,000 Americans annually, mandates that screening be accurate, efficient and cost effective.  Automation of this innovative diagnostic tool is an important step towards achieving these performance requirements, and I look forward to seeing the results of the clinical studies that VisionGate will conduct later this year."

The Cell-CT automated system harnesses the power of cutting-edge optics and computational technology that have the capability to capture images very rapidly, rendering scanned objects into 3D digital images.  All components of the Cell-CT system have been custom designed by VisionGate's scientists and engineers.  The technology is covered by 66 issued patents around the globe.

VisionGate was awarded an NIH BRDG-SPAN grant for automation of the Cell-CT platform in recognition of its potential to "improve human health and create significant value and economic stimulus."  The BRDG-SPAN program aims to accelerate the transition of research innovations and technologies toward the development of products or services that will improve human health, help advance the mission of NIH and its Institutes and Centers, and create significant value and economic stimulus. This program also aims to foster partnerships among a variety of R&D collaborators working toward these aims.  For more information, visit http://www.nhlbi.nih.gov/recovery/funding/small-biz-prog.htm.

VisionGate will be presenting at the 2012 OneMedForum Finance Conference on Tuesday, January 10, 2012 at 8:50am PST.  The conference is taking place at the Sir Francis Drake Hotel in San Francisco.

About VisionGate
VisionGate, Inc. is developing a revoluti
'/>"/>

SOURCE VisionGate, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. VisionGate Closes $2 Million Financing and Announces Collaboration to Evaluate Its 3D Cell Imaging Platform for Early Lung Cancer Detection
2. Vermillion Sharpens Focus and Streamlines Operations in 2012
3. Bionovo Announces $5 Million Financing
4. Amsterdam Molecular Therapeutics Announces € 2.5 Million Equity Raise
5. Netsmart Clients to Receive Nearly $2 Million in Meaningful Use EHR Incentive Payments
6. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
7. Fox Insurance Company Awarded $3.3 Million in Arbitration Against Former Pharmacy Benefit Manager
8. CeNeRx BioPharma Completes $4.85 Million Financing
9. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem
10. Aratana Therapeutics Completes $15 Million Series B Financing
11. InnoPharma Completes $15 Million Series A Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Proove Biosciences , the commercial ... announce a new genetic test built upon research from ... Test will provide physicians with an objective way ... levels are stratified between individuals. With this new test, ... has a genetic predisposition that will affect their pain ...
(Date:9/30/2014)... Sept. 30, 2014 CORD:USE Cord Blood Bank ... that it has entered into an Equity and Exclusive ... has licensed a series of patented technologies for the isolation ... clinical applications.  Tianhe is performing Phase I/II clinical trials ... Spain using Tianhe,s Stem Cell Educator Therapy ...
(Date:9/30/2014)... 2014 OriginOil Inc. (OTC/QB: OOIL), developer ... to clean up large quantities of water, announced today ... reported on the launch of the company's CLEAN-FRAC™ industrial ... by partner STW Resources . , Immediately upon ... day (bpd) and achieved a 99.8% reduction in Turbidity ...
(Date:9/30/2014)... 30, 2014 FemCap Inc., www.femcap.com  an ... receipt of a patent No: US, 8,795,248 B2 dated ... received FDA clearance in the U.S., 510(K) K121857, medical ... Europe. This patent is related to its menstrual cup with ... company is releasing FemmyCycle Teen, a third menstrual cup ...
Breaking Biology Technology:Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4OriginOil, Inc. Report to Shareholders: Blue Gold in West Texas 2The FemmyCycle 2
... NEW YORK, Nov. 6 Morria Biopharmaceuticals,Plc, a ... positive data from its ICH compliant Phase II ... from allergic,rhinitis. MRX-4 was given as an intranasal ... study was conducted in allergic,rhinitis patients outside of ...
... world leadership in the ... ingredients, - New S2383 flavor enhancer may be used in beverages, ... healthcare products to reduce the need for sucralose, ... (Nasdaq: SNMX ), a leading company,focused on using proprietary technologies ...
... NOVATO, Calif., Nov. 6 BioMarin,Pharmaceutical Inc. (Nasdaq: ... clinical,studies of Kuvan(R) (sapropterin dihydrochloride), Naglazyme(R),(galsulfase) and enzyme ... disease will be presented at the 58th Annual ... in Philadelphia,Pennsylvania, November 11-15, 2008., "We look ...
Cached Biology Technology:Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients 2Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients 3SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 2SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 3SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 4SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 5Data to Be Presented at 58th Annual Meeting of The American Society of Human Genetics 2Data to Be Presented at 58th Annual Meeting of The American Society of Human Genetics 3
(Date:10/1/2014)... rainforests, prairies and forests of the world can also ... according to a surprising new study led by Colorado ... , The research team analyzed 596 soil samples collected ... stunning diversity of below-ground life, most of which had ... to 16.2 percent of the organisms discovered in the ...
(Date:9/30/2014)... is published today in the first authoritative scientific study ... on both sides of the grouse moor management debate. ... the Ecohydrology of River basins) project has shown that ... support red grouse populations for gun sports, has significant ... properties, river water chemistry and river ecology. , A ...
(Date:9/30/2014)... as something that we enjoy when we visit a national ... think of ourselves as a part of nature? A bird,s ... house? , The answers to these questions reflect different ... speech and in cultural artifacts. , A new Northwestern University ... Indian Center of Chicago and the Menominee tribe of Wisconsin, ...
Breaking Biology News(10 mins):Microbes in Central Park soil: If they can make it there, they can make it anywhere 2Microbes in Central Park soil: If they can make it there, they can make it anywhere 3Grouse moor burning causes widespread environmental changes 2The cultural side of science communication 2
... . , Halle/Saale. Invasive plant species can flourish ... origin. The reasons for this can be genetic changes or ... to adapt to the newcomers. These are the conclusions of ... their research on Buddleia or the Butterfly bush (Buddleja davidii) ...
... Stanford researchers have joined the ranks of investigators for ... 14 current HHMI investigators at Stanford, 11 of which ... HHMI investigators nationwide. Stanford,s recipients are: , ... applied physics. His research group is seeking to understand ...
... linked to lung disease may have a 70-percent to ... report in the May 26 issue of Archives of ... disorder, alpha1-antitrypsin deficiency (1ATD), is one of the most ... those of European descent, according to background information in ...
Cached Biology News:When the butterfly bush blossoms 2When the butterfly bush blossoms 34 Stanford faculty named Howard Hughes Medical Institute Investigators 2Genetic mutation associated with increased risk of lung cancer 2
...
... XT is undoubtedly the most complete and ... concept of layers and subsets makes it ... for different data outputs, for example Cy3 ... as well as different subsets of genes ...
...
...
Biology Products: